Gainers
- Ocugen OCGN stock moved upwards by 143.41% to $1.96 during Wednesday's pre-market session. The market value of their outstanding shares is at $317.5 million.
- Jaguar Health JAGX stock rose 50.85% to $0.6. The market value of their outstanding shares is at $56.6 million.
- Supernus Pharmaceuticals SUPN stock increased by 33.21% to $30.0. The market value of their outstanding shares is at $1.5 billion.
- Onconova Therapeutics ONTX stock rose 22.31% to $0.52. The market value of their outstanding shares is at $97.0 million.
- Ekso Bionics Holdings EKSO stock rose 22.04% to $7.75. The company's market cap stands at $64.4 million.
- InMed Pharmaceuticals INM shares moved upwards by 21.9% to $3.73. The company's market cap stands at $26.1 million.
Losers
- Cellectar Biosciences CLRB shares fell 22.39% to $2.15 during Wednesday's pre-market session. The market value of their outstanding shares is at $57.6 million.
- Voyager Therapeutics VYGR stock declined by 10.08% to $8.12. The market value of their outstanding shares is at $304.2 million.
- Spectrum Pharmaceuticals SPPI shares fell 8.48% to $3.89. The market value of their outstanding shares is at $567.6 million.
- CNS Pharmaceuticals CNSP stock decreased by 6.2% to $1.97. The market value of their outstanding shares is at $32.8 million.
- Iterum Therapeutics ITRM stock decreased by 5.77% to $0.98. The company's market cap stands at $42.1 million.
- Citius Pharmaceuticals CTXR shares fell 5.41% to $1.05. The market value of their outstanding shares is at $58.3 million.
CLRBCellectar Biosciences Inc
$0.31003.47%
Edge Rankings
Momentum1.24
Growth-
Quality-
Value-
Price Trend
Short
Medium
Long
CNSPCNS Pharmaceuticals Inc
$3.1516.2%
CTXRCitius Pharmaceuticals Inc
$1.48-4.40%
EKSOEkso Bionics Holdings Inc
$0.4027-12.4%
INMInMed Pharmaceuticals Inc
$2.762.60%
ITRMIterum Therapeutics PLC
$1.34-%
JAGXJaguar Health Inc
$0.4250-5.35%
OCGNOcugen Inc
$0.54951.29%
SUPNSupernus Pharmaceuticals Inc
$31.260.29%
VYGRVoyager Therapeutics Inc
$3.90-4.06%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in